<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1016/j.ejmech.2019.03.019</dc:identifier><dc:language>eng</dc:language><dc:creator>Gálvez, José A.</dc:creator><dc:creator>Clavería-Gimeno, Rafael</dc:creator><dc:creator>Galano-Frutos, Juan J.</dc:creator><dc:creator>Sancho, Javier</dc:creator><dc:creator>Velázquez-Campoy, Adrian</dc:creator><dc:creator>Abian, Olga</dc:creator><dc:creator>Díaz-de-Villegas, María D.</dc:creator><dc:title>Stereoselective synthesis and biological evaluation as inhibitors of hepatitis C virus RNA polymerase of GSK3082 analogues with structural diversity at the 5-position</dc:title><dc:identifier>ART-2019-111123</dc:identifier><dc:description>GSK3082 e a hepatitis C virus RNA polymerase inhibitor e and a series of analogues with structural diversity at the 5-position were prepared from a 2,2,4,5 -tetrasubstituted pyrrolidine obtained with a well-defined stereochemistry from the 1,3-dipolar cycloaddition of the chiral imino ester derived from leucine tert-butyl ester and (R)-2,3-O-isopropylideneglyceraldehyde with methyl acrylate. The chiral 2,2-dimethyl-1,3-dioxolane moiety provided by the glyceraldehyde served as a synthetic equivalent for different substituents and functional groups and these transformations usually required mild reaction conditions and simple work-up procedures. The inhibitory activity of the resulting GSK3082 analogues was studied in vitro in a cell-based assay of the subgenomic HCV RNA replication system. Some of the analogues showed good inhibitory activity with IC50 values in the nanomolar concentration range.</dc:description><dc:date>2019</dc:date><dc:source>http://zaguan.unizar.es/record/88227</dc:source><dc:doi>10.1016/j.ejmech.2019.03.019</dc:doi><dc:identifier>http://zaguan.unizar.es/record/88227</dc:identifier><dc:identifier>oai:zaguan.unizar.es:88227</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/DGA/E45-17R</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/FIS/PI15-00663</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/CPII13-0017</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MEC/FPU13-3870</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MINECO/BFU2016-78232-P</dc:relation><dc:identifier.citation>EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 171 (2019), 401-419</dc:identifier.citation><dc:rights>by-nc-nd</dc:rights><dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>